The Trump administration is negotiating a deal with Eli Lilly (LLY) and Novo Nordisk (NVO) that would allow the lowest doses of some of their weight loss drugs to be sold to consumers at $149 for a month’s supply via TrumpRx, Liz Essley Whyte and Peter Loftus of Wall Street Journal report, citing people familiar with the matter. The deals would also result in Medicare and Medicaid covering the drugs, sources told the Journal. Trump is expected to announce the deals on Thursday morning at the White House with company executives, the people said.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Midday Fly By: Palantir reports Q3 beat, Starbucks forms China JV
- Novo Nordisk, Lilly nearing deal on obesity drug pricing, says UBS
- Novo Nordisk, Lilly nearing deal on obesity drug prices, Endpoints reports
- Eli Lilly asks European nations to scrap clawback taxes, FT says
- Eli Lilly (LLY) to Build $3 Billion European Plant to Manufacture Weight-Loss Pill